title: Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
abstract: BACKGROUND
  The therapeutic response of chronic myelogenous leukemia in myeloid blast crisis (CML-MBC) is very poor.
  
  
  OBJECTIVE
  To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells.
  
  
  RESULTS
  Thirty-four patients with CML-MBC were treated with the HA regimen and bone marrow CD34+CD7+ cells were assayed prior to and after treatment. Among 33 evaluable patients, the overall hematological response (complete/ partial hematological response and hematological improvement) was 60.1%. Seven patients (21.2%) had a cytogenetic response 12 months after treatment. In the untreated CMLMBC patients, the proportion of bone marrow CD34+CD7+ cells was much higher than in the control group (19.4 ± 7.9 vs. 4.4 ± 1.5%, p < 0.05) and decreased to 14.1 ± 7.1% (p < 0.05) after treatment. Before treatment, the proportion of CD34+CD7+ cells was lower in the patients who had a hematological response to the HA regimen than in the patients who did not respond.
  
  
  CONCLUSIONS
  The HA regimen is an effective treatment for CML-MBC and CD34+CD7+ cells may be one of the valuable clinical parameters to assess treatment effectiveness.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Li
authors.forename: Zhikui
authors.initials: Z
authors.lastname: Deng
authors.forename: Jiabin
authors.initials: J
authors.lastname: Zho
authors.forename: Banhe
authors.initials: B
authors.lastname: Ding
authors.forename: Yuye
authors.initials: Y
authors.lastname: Shi
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D019011:Antigens, CD7 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy* / Q000473:pathology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D002452:Cell Count; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D003630:Daunorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006248:Harringtonines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006402:Hematologic Diseases / Q000139:chemically induced; D000077863:Homoharringtonine; D006801:Humans; D016130:Immunophenotyping; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D022423:Myeloid Cells / Q000187:drug effects* / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D012074:Remission Induction; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D019011:Antigens, CD7; D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D008942:Mitoxantrone; D003630:Daunorubicin